The lack of effective chemotherapy, radiotherapy, or targeted therapy combinations for advanced pancreatic ductal adenocarcinoma (PDAC) has stimulated research into immunooncology strategies,1 with some early success with anti-CCR2 (C-C chemokine receptor 2)2 and anti-PD-1 (programmed cell death protein-1) strategies in patients with a mismatch repair deficiency.3 Here, PDCD1 is linked to pancreatic ductal adenocarcinoma.